Why Vertex Pharmaceuticals Is the Best Biotech Stock to Buy in August
Cystic fibrosis (CF) is a life-threatening genetic disorder that causes mucus to accumulate in the lungs, digestive system, and other organs in the body, resulting in severe damage. There is no cure for this condition, which affects more than 68,000 people in the U.S. and E.U., but it is treatable.
One biotech that has been rapidly gaining traction in treating CF is Vertex Pharmaceuticals (NASDAQ: VRTX) and its drug Trikafta. Since its approval by the U.S. Food and Drug Administration last October, Trikafta has generated more than $1.3 billion in revenue.
At the same time, the company's shares have returned 24% year to date. While some investors may feel they missed out on the biotech's remarkable rally, I think the stock's momentum is just beginning. Let's take a look at why.
Source Fool.com
